Document is current
Any future updates will be listed below
-
Authors
Neumann, Dawn
Kumar, Ambuj https://orcid.org/0000-0003-1260-6694
Van Loveren, Harry
,
Bowling, F Y
Dituri, Joseph
Dombrowski, Keith
Karlnoski, Rachel
Kessack, Kelli
Mendoza, Jorge
Miles, Shannon R
Mokin, Max
Reljic, Tea
Sanberg, Paul
Schilaty, Nathan
Schoenberg, Michael
Trivedi, Mala
Tsalatsanis, Athanasios
Viswanadhan, Narayan
Willing, Alison
Wilson, Chris
Wilson, Jason
Yadav, Hariom
Yusuf, Fayyadh
-
Funding
Funding for this research was provided by:
Florida Department of State
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 11 March 2026
First Online: 25 March 2026
Declarations
:
: This study is approved by the Institutional Review Board (IRB) at USF (IRB# 6819). Written, informed consent to participate will be obtained from all participants. The United States FDA has authorized the use of HBOT under investigational new drug (IND)/investigational device exemption (IDE; IND/IDE #: 172640).
: All have reviewed the content and have provided consent for publication of this manuscript.
: Directly related to this HBOT study, several authors’ received support from the State of Florida funding via their institutions (DN, AK, HvL, JW, JD, KD, RK, JM, SRM, TR, NS, MS, MT, AT, JW, HY, FRY). Some authors receive fees for consultation (MM, JW), expert testimony (MS, JW), honorarium (MS), or for royalties or licenses (MS), and/or own stock (MM). MS, NS, AW, JW, and FRY serve on advisory boards or workshop groups.
